An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction

Part of paid clinical trials in Columbia, Missouri.

Sponsor
University of Missouri-Columbia
Study ID
NCT03713424
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Tobacco Use Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Clavulanic Acid — DRUG
    Beta lactamase inhibitor for smoking cessation
  • Placebo oral capsule — DRUG
    placebo

Study Details

This research study is looking into the effects of clavulanic on smoking behavior in adult cigarette smokers. The primary study hypothesis is that, compared to placebo, clavulanic acid will reduce smoking over the course of the study.

Key Dates

Start date
Mar 26, 2019
Status verified
Oct 2025
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: Clav
    4-day 125 bid oral capsule administration
  • Placebo Comparator: Placebo
    4-day, twice-daily oral capsule administration

Primary Outcome Measure

Cigarette Smoking [ Time Frame: 5 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Missouri - ColumbiaColumbiaMissouri65211
Brett Froeliger, PhD
[email protected]
513-882-4785
Madhura Athreya, MS
[email protected]
573-882-2977

Find similar trials in Columbia, MO

By research site
University of Missouri - Columbia· Columbia, MO

Related Studies